Erickson Nancy A, Dietert Kristina, Enders Jana, Glauben Rainer, Nouailles Geraldine, Gruber Achim D, Mundhenk Lars
Department of Veterinary Pathology, Freie Universität Berlin, Robert-von-Ostertag-Strasse 15, 14163, Berlin, Germany.
Division of Gastroenterology, Infectiology and Rheumatology, Medical Department, Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, 12200, Berlin, Germany.
Histochem Cell Biol. 2018 Jun;149(6):619-633. doi: 10.1007/s00418-018-1664-y. Epub 2018 Apr 2.
The secreted airway mucus cell protein chloride channel regulator, calcium-activated 1, CLCA1, plays a role in inflammatory respiratory diseases via as yet unidentified pathways. For example, deficiency of CLCA1 in a mouse model of acute pneumonia resulted in reduced cytokine expression with less leukocyte recruitment and the human CLCA1 was shown to be capable of activating macrophages in vitro. Translation of experimental data between human and mouse models has proven problematic due to several CLCA species-specific differences. We therefore characterized activation of macrophages by CLCA1 in detail in solely murine ex vivo and in vitro models. Only alveolar but not bone marrow-derived macrophages freshly isolated from C57BL6/J mice increased their expression levels of several pro-inflammatory and leukotactic cytokines upon CLCA1 stimulation. Among the most strongly regulated genes, we identified the host-protective and immunomodulatory airway mucus component BPIFA1, previously unknown to be expressed by airway macrophages. Furthermore, evidence from an in vivo Staphylococcus aureus pneumonia mouse model suggests that CLCA1 may also modify BPIFA1 expression in airway epithelial cells. Our data underscore and specify the role of mouse CLCA1 in inflammatory airway disease to activate airway macrophages. In addition to its ability to upregulate cytokine expression which explains previous observations in the Clca1-deficient S. aureus pneumonia mouse model, modulation of BPIFA1 expression expands the role of CLCA1 in airway disease to involvement in more complex downstream pathways, possibly including liquid homeostasis, airway protection, and antimicrobial defense.
分泌型气道黏液细胞蛋白氯化物通道调节因子1(CLCA1)通过尚未明确的途径在炎症性呼吸系统疾病中发挥作用。例如,在急性肺炎小鼠模型中,CLCA1缺乏导致细胞因子表达减少,白细胞募集减少,并且已证明人CLCA1能够在体外激活巨噬细胞。由于几种CLCA物种特异性差异,在人和小鼠模型之间转换实验数据已被证明存在问题。因此,我们在纯小鼠的离体和体外模型中详细表征了CLCA1对巨噬细胞的激活作用。仅从C57BL6/J小鼠新鲜分离的肺泡巨噬细胞而非骨髓来源的巨噬细胞在CLCA1刺激后会增加几种促炎和趋化细胞因子的表达水平。在调控最为强烈的基因中,我们鉴定出了具有宿主保护和免疫调节作用的气道黏液成分BPIFA1,此前未知气道巨噬细胞会表达该成分。此外,来自金黄色葡萄球菌肺炎小鼠体内模型的证据表明,CLCA1也可能会改变气道上皮细胞中BPIFA1的表达。我们的数据强调并明确了小鼠CLCA1在炎症性气道疾病中激活气道巨噬细胞的作用。除了上调细胞因子表达的能力(这解释了先前在Clca1缺陷型金黄色葡萄球菌肺炎小鼠模型中的观察结果)外,BPIFA1表达的调节将CLCA1在气道疾病中的作用扩展到参与更复杂的下游途径,可能包括液体稳态、气道保护和抗菌防御。